Start › Rak płaskonabłonkowy głowy i szyi › Georgia › Atlanta
Badania kliniczne dla Rak płaskonabłonkowy głowy i szyi w mieście Atlanta, GA
24 badań dla Rak płaskonabłonkowy głowy i szyi szuka uczestników w ośrodkach w mieście Atlanta i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekrutacjaFaza 1
- Emory University, Atlanta
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
RekrutacjaFaza 3
- Emory University, Atlanta
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RekrutacjaFaza 2
- Emory University Hospital Midtown, Atlanta
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
RekrutacjaFaza 3
- Emory University Hospital Midtown, Atlanta
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
RekrutacjaFaza 1
- Emory University, Atlanta
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RekrutacjaFaza 2
- Emory Proton Therapy Center, Atlanta
- Emory University Hospital Midtown, Atlanta
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RekrutacjaFaza 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
RekrutacjaBadanie obserwacyjne
- Morehouse, Atlanta
- Piedmont Healthcare, Atlanta
- Winship Cancer Institute, Emory University, Atlanta
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RekrutacjaFaza 2
- Emory University School of Medicine, Atlanta
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
RekrutacjaFaza 2/3
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RekrutacjaFaza 1/2
- Winship Cancer Institute - Emory University, Atlanta
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Emory University, Atlanta
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Rekrutacja
- Emory Midtown University Hospital/Winship Cancer Institute, Atlanta
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Winship Cancer Institute, Emory University, Atlanta
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
RekrutacjaFaza 3
- GSK Investigational Site, Atlanta
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
RekrutacjaFaza 2
- USA10-0, Atlanta
Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
Rekrutacja
- Emory University Hospital, Atlanta
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RekrutacjaFaza 3
- Emory University, Atlanta
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
RekrutacjaFaza 1/2
- Research Site 111, Atlanta
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
RekrutacjaFaza 1
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
RekrutacjaFaza 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RekrutacjaFaza 1/2
- Research Site 114, Atlanta
- Research Site 139, Atlanta
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
RekrutacjaWczesna faza 1
- Emory University Hospital Midtown, Atlanta
A Beta-only IL-2 ImmunoTherapY Study
RekrutacjaFaza 1/2
- Emory - Winship Cancer Institute, Atlanta
Badania dla Rak płaskonabłonkowy głowy i szyi w innych miastach
- Houston, TX47 badań
- Los Angeles, CA42 badań
- Boston, MA40 badań
- Nashville, TN39 badań
- New York City, NY39 badań
- St. Louis, MO28 badań
- Arlington, VA26 badań
- Chicago, IL26 badań
- Philadelphia, PA26 badań
- San Antonio, TX22 badań
- Pittsburgh, PA22 badań
- New Haven, CT22 badań
Inne badania w mieście Atlanta
- Nowotwory (wszystkie typy)49 badań
- Niedrobnokomórkowy rak płuca47 badań
- Szpiczak mnogi42 badań
- Rak piersi41 badań
- Rak prostaty33 badań
- Ostra białaczka szpikowa31 badań
- Rak jajnika29 badań
- Rak jelita grubego i odbytnicy29 badań
- Rak płuc29 badań
- Nowotwór przerzutowy28 badań
- Duża depresja25 badań
- Niewydolność serca25 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.